

# Specialty Guideline Management

## Lumvoa

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name    |
|------------|-----------------|
| Lumvoa     | veligrotug-vvze |

### Indications

#### FDA-approved Indications<sup>1</sup>

Lumvoa is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.

All other indications are considered experimental/investigational and not medically necessary.

### Documentation

Submission of the following information is necessary to initiate the prior authorization review:

Supporting chart notes or medical record indicating moderate-to-severe disease.

### Exclusions

Coverage will not be provided for repeat series of Lumvoa infusions.

# Prescriber Specialties

This medication must be prescribed by or in consultation with an ophthalmologist or endocrinologist.

## Coverage Criteria

### Thyroid Eye Disease (TED)<sup>1-3</sup>

Authorization of 6 months may be granted for treatment of TED when all of the following criteria are met:

- Member is 18 years of age or older.
- Member has moderate-to-severe (active and inactive) disease (see Appendix A).
- Member will not exceed a one-time treatment course consisting of 5 infusions given once every 3 weeks at a dose of 10 mg/kg.

## Appendix

### Appendix A: Disease Severity Assessment<sup>2</sup>

- Mild disease, at least one of the following:
  - Minor lid retraction (<2 mm)
  - Mild soft-tissue involvement
  - Exophthalmos <3 mm above normal for race and gender
  - No or intermittent diplopia
  - Corneal exposure responsive to lubricants
- Moderate-to-severe disease, at least one of the following:
  - Lid retraction ≥2 mm
  - Moderate or severe soft-tissue involvement
  - Exophthalmos ≥3 mm above normal for race and gender
  - Inconstant or constant diplopia
- Sight-threatening disease, at least one of the following:
  - Dysthyroid optic neuropathy (DON)
  - Corneal breakdown

## References

1. Lumvoa [package insert]. Waltham, MA: Viridian Therapeutics, Inc.; June 2026.
2. Bartalena L, Kahaly L, Baldeschi L, et al. The 2021 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' orbitopathy. *Eur J Endocrinol*. 2021;185(4):G43-G67.
3. Burch HB, Perros P, Bednarczuk T, Cooper DS, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. *Thyroid*. 2022 Dec;32(12):1439-1470.